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ABSTRACT 
Introduction 
South Africa has more people living with HIV than any other country in the world.1 Women 
infected with HIV have a high risk in the development of cervical dysplasia and cancer of the 
cervix more so than women who are not infected.2,3  
Methods 
A cross-sectional descriptive study was carried out by reviewing cervical smears of HIV 
positive women in a district hospital. Three hundred and ninety cervical Pap smears were 
classified according to the Bethesda system. Adherence was measured by the patient’s report 
and viral load. Data was collected through the use of self administered questionaire and data 
capture sheet.  
Results 
The prevalence of abnormal Pap smears was 57 per cent and LSIL was the commonest 
abnormality seen (142/390, 36%). Eighty-four per cent (328/390) had stage 1 WHO-HIV 
classification. WHO stage 3 participants seemed to be three times more likely to have 
abnormal Pap smears than those with WHO stage 1 (OD 3.3, STD. error 1.70, p=0.018, 95% 
CI 1.23-9.04). Abnormal pap smears were seen more in participants with CD4 cell count ≤ 
350 cells/µL  as compared to participants with CD4 cell count ≥ 500 cells/µL { 122/172, 
(71.00 %)  vs  48/117, (41.03%), p-0.000, 95% CI : 0.09-0.37}. Similarly, participants who 
did not use HAART  had more abnormal results as compared to  those who used HAART 
{42/60(70.00%)  vs 180/330 (55.00%), p-0.028, 95% CI 0.28-0.93}.Adherence to HAART 
did not show any link with abnormal smears. 
Conclusion 
The more immune-suppressed a woman is, the higher the risk of developing cervical cancer 
precursors. The high risk group in this study was found to be the participants with the CD4 
v 
 
cell count of ≤ 350 cells/µL and the viral load ≥1000 copies/mm3. The self-reported 
adherence level did not show any impact.   
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CHAPTER 1 
INTRODUCTION 
 
1.1 Background and rationale: 
 
Sixty-eight percent of all people living with HIV resided in the Sub-Saharan Africa, a region 
with only 12.00% of the global population, and where women are more than 50.00% of the 
epidemic.1 The epidemic continues to be most severe in Southern Africa, with South Africa 
having more people living with HIV(an estimated 5.6 million) than any other country in the 
world.1 
Women infected with HIV have a high risk of developing cervical dysplasia and cancer of the 
cervix higher than women who are not infected.2,3 
Cervical cancer is the second most common cause of cancer mortality in women worldwide, 
and the leading cause of cancer mortality in Africa, where access to screening programmes is 
limited.1,2 Multivariable factors have been identified as factors in the development of cervical 
cancer.4 Among these multivariable factors, HIV-positive status was established as a risk 
factor in the pathogenicity of cervical cancer, 4 and the CDC in 1993 declared it an acquired 
immunodeficiency syndrome (AIDS) defining illness.5 In addition, Moodley et al in South 
Africa described cervical cancer and infection with HIV as important public health 
problems.6  
Cervical cancer is a preventable condition. Some authors advocated Pappanicolaou screening 
as an early screening tool for cervical cancer. 6,7 The late Dr George Papanicolaou invented 
the Pap smear in 1940. The Pap smear has been found to be the only screening method that 
shown to reduce mortality from cervical cancer.8  
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According to the South African clinical guidelines of 2010 on the management of HIV 
patients all HIV-positive women need cervical cancer screening on diagnosis, and if normal, 
every three years irrespective of HAART treatment.9 Hence, the justification of a cervical 
smear as a prerequisite to a pre-HAART work-up by some institutions was found justified. 
10,11 
There are several publications that have reviewed different risk factors associated with the 
abnormal Pap smears in HIV-positive women, such as the CD4 cell count and antiretroviral 
therapy,  but not much is known about other factors like WHO staging and adherence to 
effective antiretroviral therapy use on abnormal cervical smears in HIV-infected women. 
1.2 Motivation for the study  
 
This observation led the researcher to undertake a study looking at factors other than the 
known ones associated with the development of abnormal cervical smears in HIV-infected 
women in this hospital, such as WHO staging and HAART use, and adherence to them. It is 
hoped that this study will help clinical services to focus on Pap smears amongst HIV-infected 
women most at risk of developing cervical cancer.  
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CHAPTER 2 
LITERATURE REVIEW 
2.1 Introduction 
 
The prevalence of HIV infection is reported to be 11.50% in South Africa.1 It is estimated 
that approximately 1,500 people are daily infected with the disease in South Africa.1 South 
Africa has the largest burden of HIV/AIDS and is currently implementing the largest 
antiretroviral treatment (ART) programme in the world.12 
Studies have shown that HIV-positive women are at an increased risk of developing cervical 
squamous intraepithelial lesions (SIL) and cervical cancer.4,6,13 In developed countries, where 
screening is high and of good quality, the Pap smear screening efforts have reduced invasive 
cervical cancer incidence by about 70.00% to 90.00%.14,15 
2.2     Prevalence of cervical cancer or cervical dysplasia in HIV-seropositive women. 
 
Cervical cancer is the second most common type of cancer among women in South Africa, i.e 
one in every 31 women will, within their lifetime, develop this form of cancer.16 The 
prevalence of abnormal Pap smears varies from study to study: so far, it ranges between 
36.00% 14 to 55.50% 17 in HIV-infected women. It was found to be higher (66.30%) among 
HIV- infected females before initiation to HAART.6 The prevalence of abnormal Pap smears 
in HIV-negative women in Soweto, Southern Africa was 6.70%.18 This demonstrates that 
immunosuppression from HIV infection is a potential risk factor in the development of 
cervical dysplasia. 
2.3        Classification of cervical cancer/dysplasia 
 
A classification from a workshop initiated by the US National Council Institute developed the 
2001 Bethesda System19 whereby the cytology results are named squamous intra-epithelial 
lesions (SIL), which are also divided into atypical squamous cells of undetermined 
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significance (ASCUS), low-grade SIL (LGSIL-similar  to histology result of CIN 1) and 
high- grade SIL (HGSIL- similar to the histology result of CIN 2 and CIN 3), and squamous 
cell carcinoma (SCC).20 
2.4        Ways of  detecting  cervical abnormality 
 
There are different ways of detecting abnormal cervical lesions. In most areas in South 
Africa, a conventional Pap smear is used. 
  
 Pap smear 
 
The Papanicolaou (Pap) smear is a primary screening tool which is simple, safe, non-
invasive, and an effective method for the detection of pre-cancerous, cancerous and non-
cancerous changes in the cervix and vagina.21 The use of the Pap smear has reduced 
morbidity and mortality from invasive cancer in various population groups.22,23 There are two 
types of cytology screening: the conventional cytology screening using the dry slide test 
using a wooden spatula, and the liquid-based cytology screening. The liquid-based and 
conventional cytology methods were found to be equivalent in the detection of cervical 
epithelial abnormalities.24,25 
The public health sector in South Africa uses the conventional Pap smear, since it is cost 
effective. 
2.5  Causes / Association  of cervical cancer 
2.5.1  Epidemiological association 
 
Young age at first coitus (before 20 years), multiple sexual partners, a sexual partner with 
multiple sexual partners, young age at first pregnancy, high parity and low socio-economic 
status are factors found to be associated with cervical cancer and its precursors.26 
Among  sexually transmitted diseases (STDs) other than Human papillomavirus (HPV), 
Chlamydia trachomatis may be an important HPV cofactor for cervical carcinogenesis.27 
HPV is the main cause of cervical neoplasia.272Recent studies of the aetiology of cervical 
neoplasia aimed to identify factors that may influence susceptibility or progression of HPV 
6 
 
infection to cervical neoplasia. Identification of the above cofactors is important because 
these factors can be amenable to prevention.27  
Some studies have demonstrated that HIV-positive women are at an increased risk of 
developing cervical SIL,6,28 and another study  has linked HIV-positive women with cervical 
cancer.13 HIV-negative women (6.70%)18 have a lower prevalence of cervical cancer than 
HIV- positive women (36.00%).14  Therefore, being HIV-positive may be a risk factor for the 
developing of cervical SIL and cervical cancer. 
 In studies by Tansupswatdikul in Thailand 29 and Denny et al 2 in South Africa, it was found 
that low a CD4 cell count was significantly associated with the presence of abnormal 
cytological lesions. 
Another study revealed that there was a significant association between HPV infection and 
the number of sexual partners in the last six months (p≤ 0.001) in a study conducted in 
United States of America.30 This study also suggested that the use of condoms might protect 
against the incidence of HPV in HIV-infected women with multiple recent sexual 
partners.30A case-control study done in Johanessburg reported a low prevalence of abnormal 
Pap smear in women who reported current condom use as compared to women who did not 
use condom.28 
2.5.2 Association of SILs and cervical cancer with HPV 
 
During the 1990s, epidemiological studies supported by molecular technology, provided 
evidence on the causal role of some HPV infections in the development of cervical cancer. 
This association was evaluated under all proposed sets of causality criteria and endorsed by 
the scientific community and major review institutes. The finding was universally consistent, 
and to date there are no documented alternative hypotheses for the aetiology of cervical 
cancer. The HPV types considered by this study as human carcinogens were 16, 18, 31,33 
,35, 45, 51, 52, 58 and 59.31  
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As a result of HIV-induced immune impairment, there is an increased probability that HPV 
infection will become persistent in HIV-infected women, and evolve into precancerous and 
cancerous lesions of the cervix.32,33 
Other studies found an association between the development of SILs and other HPV types 53 
and 56 for LSIL, and 35, 51, 52, 58, 66, 69 and 73 for HSIL in HIV-positive women.34,35 
HPV typing and screening is avalaible in private practice in South Africa. However, it is too 
expensive for the public sector at this point. HIV-infected women also have high rates of 
HPV infection (up to 90.00% in some studies)35,36 which would make HPV testing an 
ineffectual screening test in South Africa HIV-infected women. 
2.5.3 Effect of CD4 cell count levels on abnormal Pap smears 
 
Women with HIV infection are at increased risk for cervical disease and this risk increases 
with severe immuno-suppression.4 
Another study reported that lower CD4 cell count levels (less than 200 cells/µL vs more than 
500 cell/µL) were consistently associated with all grades of cervical neoplasia. 28 In a 
prospective study of untreated HIV-1-infected women in Cape Town 2, Denny et al found 
that abnormal cytology was strongly correlated with low CD4 cell counts. Thus, the more 
immunocompromised the patient, the higher the chance of developing cervical dysplasia. 
2.5.4 Effect of HAART on abnormal Pap smears 
 
Highly active antiretroviral therapy (HAART) was shown to decrease the HIV viral load, 
increase the CD4 cell count, and decrease most opportunistic infections in HIV-infected 
patients. Since the introduction of HAART there has been a reduction in the incidence of 
certain malignancies in HIV-infected individuals.37,38 However, studies on the impact of 
HAART on the natural history of SILs have produced inconsistent results.39,40 As HAART 
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has become increasingly available in the public health sector in South Africa, the life span of 
HIV-infected women has increased.41 
According to Heard et al 42 the regression of SIL was defined as a regression to normality or 
to a lower grade. This regression was noticed from high-grade SIL to low-grade SIL (31/80, 
38.80%.) and to normal (6/80, 7.50%).42 Similarly, it was also reported that women on 
HAART were more than twice as likely than non-HAART users to demonstrate regression in 
consecutive cervical smears compared.43 These two studies suggested that HAART had a 
positive effect on the regression of cervical lesions. In view of the above, it was also found 
that HAART use was associated with the reduction of the cervical lesions incidence among 
HIV-positive women.44  
Contrary to the above, some findings reported no association between current HAART use 
and the progresssion of cervical neoplasia.28 However, it was found that HIV-infected women 
not on HAART were at a higher risk of developing HSIL than those on HAART.17  
From the above studies, it can be seen that there was controversial evidence supporting the 
effects of HAART on cervical lesions. 
2.5.5  Effect of use of and adherence to HAART on abnormal Pap smears. 
Effective use HAART was defined as a reduction in the viral load by > 90.00% or to 
undetectable levels for at least two sequential visits starting within 12 months of HAART 
initiation.46 Regular monitoring  of  the viral load is critically important to identify poor 
adherence to therapy, or treatment failure. HAART, the viral load should be undetectable 
(<50 copies/ml) after 16 to 24 weeks of therapy.45 Viral failure is defined as a sustained 
increase to >1000 copies/ml despite a good adherence.45  Adherence to the treatment is 
defined as self-reported use of HAART as prescribed ≥ 95.00% of the time for at least two 
sequential visits, starting within 12 months of HAART initiation.46 Although self-reporting of 
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adherence is a good measure of treatment effectiveness,45 it has interview bias. The viral load 
is a far better guide to true adherence to HAART.45 
The WHIS (Women’s Interagency HIV Study) cohort study proved that the use and 
adherence to HAART  was associated with a significant reduction of HPV infection and SILs 
among HIV-infected women who took HAART; this may be a reason why HIV-positive 
women live longer without an increased rate of cervical cancer.46 Abnormal cytology was 
found to be strongly correlated with high HIV viral loads in a Cape Town study by Denny et 
al.2  
Thus, HAART (viral load suppression) use may reduce the progression rates and/or increase 
the regression of cervical lesions. Adherence to HAART needs to be evaluated if HAART 
affects the rates of cervical dysplasia progression and/or regression in HIV- positive women. 
The findings may stand as a call to the opportunity of offering HAART to all HIV- infected 
women particulary in developing countries where cervical cancer screening is limited. 
2.5.6  WHO staging and abnormal Pap smears 
 
Many countries do not have CD4 cell count tests, and rely on WHO staging. There is a 
paucity of studies looking at the association between WHO staging and cervical dysplasia. 
This study hoped to help these countries to stratify the risk of developing cervical 
abnormality or cervical cancer in HIV-positive women, based on WHO staging (See 
annexure 7). This study aimed to improve on the available knowledge on the abnormal Pap 
smear in HIV-infected women. 
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CHAPTER  3 
MATERIAL AND METHODS 
3.1 Definition of variables 
 
WHO staging: Clinical staging or classification of HIV/AIDS for adults and adolescents 
with confirmed HIV infection. (see annexure 8) 
Adherence to HAART: Self-reported use of HAART as prescribed ≥ 95.00% of the time 
and a reduction in the viral load by > 90.00% or to an undetectable levels for at least two 
sequential visits starting within 12 months of HAART initiation. 
 Abnormal cervical smears: Presence of pre-cancerous or squamous intraepithelial lesions 
on cervical smears.  
 HIV-infected women: Women who have tested positive for the human immunodeficiency 
virus. 
DR YUSUF DADOO HOSPITAL: Is a level one district hospital with 245 approved  beds, 
situated in Mogale City in Krugersdorp. Mogale City is situated in the Western part of 
Gauteng province. Phedisong clinic is a HIV clinic in the Dr Yusuf Dadoo Hospital.  
MULTIPLE SEXUAL PARTNERS: Is defined in this study as more than one lifetime 
sexual partner.  
3.2 Aim:  
 
To assess the association of WHO staging, adherence to HAART with abnormal cervical 
smears among  HIV-infected women attending Dr Yusuf Dadoo Hospital. 
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3.3 Objectives: 
 
1. To determine the prevalence of abnormal cervical smears in HIV-infected 
women at Dr Yusuf Dadoo Hospital.  
2. To describe the basic characteristics (sociodemographic, sexual activities and 
reproductive health) of the participants in the study sample.  
3. To describe the clinical characteristics of the participants including WHO 
staging, CD4 cell count levels, viral load, treatment on HAART and not on 
HAART, the period on HAART, adherence to treatment or not. 
4. To acertain whether the WHO staging and use of and adherence to HAART 
have any correlation with abnormal cervical smears. 
3.4 Study area and setting: 
 
This study was conducted in an HIV clinic (Phedisong Clinic) of the Dr Yusuf Dadoo 
Hospital. Phedisong Clinic dealt with an estimated monthly average of 250 patients this year, 
who were cared for by three nurses and two doctors.The total number of patients seen in 2011 
was 1260. About 70.00% of these patients were female, of which 56.00% were on HAART 
and 44.00% were not on HAART. All women were offered a Pap smear when they came to 
the clinic.  
3.5  Study design  
  
The study design was  a quantitative, cross-sectional, descriptive survey. 
3.6 Study period 
 
The pilot study and its analysis were conducted from 15 March to 28 March 2013. The actual 
research was conducted from the 1 April to 30 June 2013. 
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3.7 Study population 
 
 All HIV-infected women who attended Phedisong Clinic at the time of the research and who 
gave consent to participate in the study formed the study population. The total number of 
HIV-infected women who attended this clinic during the study period was 500. 
3.8  Study sample, sample size and sampling 
 
With the help of the statistician the minimum sample size was calculated using the formula:  
Sample size= Z2 x P x (1-P)/ C2  where Z= 95% Confidence interval (1.96 SD), P= 
Prevalence of  HIV patients with abnormal Pap smears. Since there was no study on the 
prevalence of abnormal cervical smears in this district, the prevalence of abnormal cervical 
smears was considered to be 50.00%,  C= Significance level (0.05). The calculated sample 
size was (1.96)2 x 50 x (1-50)/ (0.05)2 = 384. An attempt was made to see all HIV- positive 
women. The study sample was 390. 
3.9 Inclusion criteria 
 
 HIV-positive (by two different rapid tests), Western blot, ELISA or HIV viral 
load>5000 copies/ml 
 Willing to do one Pap smear test at the time of consultation 
 Women aged 18-65 years 
 Not menstruating but screened after menstruation was over 
 Was able to give consent 
 Was able to follow the study protocol 
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3.10  Exclusion criteria 
 
 Was pregnant at the time of the study 
 Was clinically active with sexually transmitted disease as determined by the clinical 
history and/or physical examination and was advised to participate after adequate 
treatment by syndromic management 
 Known and previous hysterectomy with removal of the cervix 
 Significant medical illness/mental illness that investigator felt that it would prevent 
the participant from complying with the protocols or  would place the participant at 
medical risk 
 Pilot study participants 
3.11 Data collection 
 
The researcher worked in this clinic for three months. Every day, the researcher briefly 
introduced himself to the potential participants and explained the purpose of the study, the 
questionnaire to them and gave the consent form to all the female patients.Those who signed 
the consent form met the professional nurse at the front desk who directed them to the 
researcher’s room. The questionnaire was filled in by the researcher. The researcher looked 
into their files and collected data such as CD4 cell count levels, viral load, HAART or not, 
period on HAART, and whether the patient was adherent or not, using a different data 
capture sheet which was linked to the questionnaire. They then did a clinical examination and 
WHO staging. A Pap smear test using a standard slide preparation was performed in the 
presence of a female nursing assistant (chaperone), using a wooden spatula. After the 
collection of  the Pap smear, the sample and completed laboratory forms were sent to the 
National Health Laboratory Services (NHLS) for cytology evaluation. The relevant treatment 
was prescribed for the patients by the researcher. The patient was given a monthly 
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appointment to follow up on the results. The relevant education and/or referral for treatment 
for HIV or high grade dysplasia was given to the patients at this visit, as per the South 
African standard of care. At the end of each day, the researcher collected all the 
questionnaires and kept them safely in a locked cupboard. Each questionnaire had a unique 
number identifier to maintain confidentiality. The results were collected after a month by the 
researcher, and entered onto the data capture sheet (The Bethesda classification system was 
used since that is the system used by the NHLS).18 The questionnaire was anonymized by 
having the same code as the respondents’ Pap smear, for statistical analysis. The identity of 
the patient and the patient’s unique number identifier were transferred to a separate MS-Excel 
spreadsheet which was password-protected; only the researcher was able to access it to 
identify the Pap smear results. 
3.12 Questionnaire and data capture sheet (See annexure 1 and 2) 
 
The first tool was a directed questionnaire and was written in English, as the researcher 
conducted the data collection. The researcher sought the help of a professional nurse for the 
participants who did not speak English. It was a simple, structured and closed-ended 
questionnaire, created from many articles looking at the factors associated with abnormal Pap 
smears in HIV-positive women.  
The questionnaire was divided into two sections. 
 
 Sociodemographic characteristics like the unique number identifier, age, race, marital 
status, employment status and educational level were discussed under questions 1-8. 
 Sexual activity included age of first sexual intercourse, age of first pregnancy, number 
of sexual partners, gravidity and parity, type of contraceptive and history of STDs. 
These were discussed under questions 9-17. 
The data capture sheet was linked to the questionnaire in order to collect the clinical factors 
at the time of the Pap smear test. These clinical factors  included WHO staging, CD4 cell 
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count, viral load, on HAART or not, period on treatment, adherent or not and current Pap 
smear results.  
 3.13 Pilot Study  
 
The researcher conducted a pilot study in this clinic with a sample of 10 participants. The 
pilot study was conducted in March 2013 and then analysed. The data were coded and not 
used for the final analysis. These participants were excluded from the research sample and 
were given treatment for HIV or high grade dysplasia as per the South African guidelines. 
The researcher used this clinic because of convenience in terms of costs of travel and time, as 
the researcher was working in the same hospital. The aim of this pilot study was to: 
 Estimate the time to complete the questionnaire. 
 
 Identify questions that needed to be modified, added or removed. 
 
From the findings of the pilot study, the time to complete the questionnaire was found to be 
15 minutes. There were no sensitive questions that needed to be modified or removed as it 
seemed that the participants understood the questionnaire, the procedures and were willing to 
participate (they answered the questions without complaint or hesitation). Hence, the final 
questionnaire was prepared to be used in the main study. 
3.14  Data analysis 
 
 Data entry: Data was entered onto an MS-Excel spreadsheet and the data was cleaned 
to exclude missing values, inconsistencies and extreme values. The extreme values 
were rechecked with the files and corrected as needed. 
 Data analysis: Data was imported from the MS-Excel spreadsheet to the statistical 
software (STATA vs 10). Two statisticians helped with the analysis of the data. 
Descriptive analysis of the categorical variables was done and the results were presented 
using frequencies and percentages, whereas for continous variables means, median and 
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standard deviation were used. The Chi-square test was used to determine the association 
between WHO staging and adherence to HAART with abnormal Pap smears. Statistical 
parameters like the 95.00% confidence interval were used to confirm the strength of 
associations. The p <0.05 was considered as statistically significant. 
  3.15 Ethical considerations 
 
   The questionnaire was anonymized; hence confidentiality was maintained. The 
identity of the patient and the patient’s unique number identifier were transferred onto a 
separate MS-Excel spreadsheet which was password-protected, and only the researcher was 
able to access it to identify the Pap smear results. 
 Patient participant letters and informed consent forms were copied. One copy was 
given to all the women in the HIV clinic and the original copy was saved by the researcher. 
Only those who signed the consent form were considered for the study. The participants who 
did not speak/read English were offered a translation of the above-mentioned letters by the 
professional nurse. They had the right to refuse to participate in the study, and this right was 
respected (See annexure 3). The participants found with anbormal Pap smears or detectable 
viral load results were managed as per South African’s guidelines and those found with an 
undectable viral load were encouraged to be adherent to the treatment.   
 Written permission was obtained from the CEO of Dr Yusuf Dadoo Hospital in order 
to conduct this study in this clinic. (See annexure 4). 
 Written permission from the Director of the West Rand Health District was obtained. 
(See annexure 5). 
 An ethics clearance was sought from the Human Research Ethics Committee of the 
University of Witswatersrand. (See annexure 7) 
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3.16 Bias 
 
Information bias could not be excluded, as it was self-reported by the participants. 
3.17  Funding of the research 
 
The research was funded by the researcher’s personal funds. 
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CHAPTER 4 
RESULTS 
This chapter represents the results of the study conducted to assess the association of WHO  
staging and adherence to HAART with abnormal cervical smears among HIV-infected 
women attending Dr Yusuf Dadoo Hospital.  
4.1  Number of participants 
 
A total number of 500 hundred HIV-infected women were targeted to participate in the 
research; three hundred and ninety-eight participants gave consent to participate in the study 
and had Pap smear tests done. One hundred and two HIV-infected women did not participate 
in the study because of the following reasons:  
 Not willing to participate in the study or to give consent (N=77) 15.40% 
 Below 18 years of age (N=10) 2.00% 
 Above 65 years of age (N=5) 1.00% 
 Participants who participated in the pilot study (N=10) 2.00% 
From the participants who took part in the study, only 390 Pap smears results were retrieved.  
Eight Pap smear results were missing (all results were retrieved from the laboratory (NHLS) 
and those missing could not be traced). Hence, the total number of participants was 390. The 
total response rate was 78.00 percents. 
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4.2.  Sociodemographic characteristics of the participants 
 
Table 4.1   Sociodemographic characteristics of the participants 
 
The age range of the participants in the study was from 21 to 65 years; twenty-four per cent 
(93/390) were in the 35-39 years age group, and ninety-eight per cent (381/390) were 
Africans. Eighty-two per cent (321/390) of the participants were either single, cohabiting, 
widowed or divorced. Sixty-six per cent (258/390) of the participants were employed and 
seventy-five per cent (291/390) had pre-matric qualification.Thirty-four per cent (132/390) of 
the participants not employed were either unemployed, students or pensioners.  
 
Variables Number of participants 
N=390 
Percentages 
% 
Mean +/-SD 
Age group (Years)    
Less than 30 63 16.15 38+/-8.67 
30-34 68 17.44  
35-39 93 23.85  
40-44 80 20.51  
More than 45 86 22.05  
Ethnic group    
African 381 97.69  
Coloured 9 2.31  
White 0 00.00  
Indian 0 00.00  
Marital status    
Not married 321 82.31  
Married 69 17.69  
If not married, what is your status N=321   
Single 184 47.18  
Cohabiting 108 27.69  
Widowed 21 5.38  
Divorced 8 2.05  
Employment status N=390   
Not employed 132 33.85  
Employed 258 66.15  
If you are not working, what is your professional status N=132   
Unemployed 126 95.45  
Student 4 3.04  
Pensioner 2 1.51  
Educational status N=390   
No education 11 2.82  
Pre-matric 291 74.62  
Matric 59 15.13  
Post-matric 29 7.44  
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4.3.  Reproductive health and sexual activities of the participants 
 
Table 4.2 Reproductive health and sexual activities of the participants 
Variables Number of 
participants 
N=390 
Percentages 
% 
Age group at the first sexual encounter   
Less than 10 years 1 0.26 
10-14 years 10 2.56 
15-19 years 296 75.90 
20-24 years 78 20.00 
More than 25 years 5 1.28 
Age group at the first pregnancy   
Never fell pregnant 16 4.10 
Less than and equal to 24 years 302 77.43 
25-30 years 56 14.36 
Greater than 30 years 16 4.10 
Number of lifetime pregnancies   
Never fell pregnant 16 4.10 
1-4 pregnancies 338 86.67 
Greater than  and equal to 5 pregnanies 36 9.23 
Number of children born after completing 7 months of pregnancy   
0 26 6.67 
1-4 344 88.21 
Greater than and equal to 5 20 5.13 
Number of sexual partners in a lifetime   
1 31 7.95 
Greater than and equal to 2 359 92.05 
History of Sexually Transmitted Diseases (STDs)   
No history of STDs 236 60.51 
Had history of STDs 154 39.49 
Types of STDs reported N=154  
Vaginal discharge 120 77.92 
Genital ulcer 8 5.51 
Genital warts 4 2.59 
Herpes simplex 4 2.59 
Herpes simplex & Vaginal discharge 4 2.59 
Genital ulcer & Herpes simplex 4 2.59 
Genital ulcer & Vaginal discharge 4 2.59 
Genital warts & Vaginal discharge 2 1.29 
Genital ulcers & genital warts 2 1.29 
Not sure of the type of STDs 2 1.29 
Use of contraception ( prevention) N=390  
Did not use contraception 88 22.56 
Did use contraception 302 77.44 
If using contraception, what types of contraception did they use? N=302  
Condom 182 60.26 
Other methods (Bilateral tubal ligation, Intra uterine device &abstinence) 58 19.20 
Injection 23 7.61 
Oral Contraceptive Pills 6 1.98 
Condom &Injection 19 6.29 
Condom & other methods(Bilateral tubal ligation, Intra uterine device 
&abstinence) 
7 2.31 
Condom & Oral Contraceptive Pills 3 0.99 
Injection & other methods(Bilateral tubal ligation, Intra uterine device 
&abstinence) 
2 0.66 
Oral Contraceptive & Other methods(Bilateral tubal ligation, Intra uterine device 
&abstinence) 
2 0.66 
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Seventy-six per cent (296/390) of the participants had their first sexual encounter between the 
age of 15 and 19 years, and seventy-seven per cent (302/390) had their first pregancy at the 
age below or equal to 24 years. Eighty-seven per cent (338/390) of the participants had one to 
four pregnancies in their lifetime and eighty-eight per cent (344/390) had one to four children 
born after completing seven months of pregnancy. Ninety-two per cent (359/390) of the 
participants had multiple lifetime sexual partners. Sixty-one per cent (236/390) of the 
participants reported that they had had no STDs in their lifetime. Seventy-eight percent 
(120/154) of the participants who reported as having had STDs were having vaginal 
discharge. Seventy-seven per cent (302/390) of the participants had used contraception and 
sixty per cent (182/302) used condoms as a preventive method. 
4.4  Clinical characteristics 
 
Table 4.3.1  Clinical characteristics of the participants 
Variables Number of 
participants 
(N=390) 
Percentages  
% 
Median 
WHO staging    
Stage 1 328 84.10  
Stage 2 36 9.23  
Stage 3 26 6.67  
Stage 4 0 0.00  
Most recent CD4 cell count levels at the time of the pap 
smear (in cell/µL) 
   
Less than 200 59 15.13  
200-349 113 28.97 381 
350-499 101 25.90  
Greater than and equal to 500 117 30.00  
Viral load (in copies/ml)    
Viral load not done (Participants not on HAART and participants 
on HAART for a period of less than 6 months) 
66 16.92  
Less than 50 198 50.77  
50-399 69 17.69  
400-999 16 4.10  
Greater than and equal to 1000 41 10.51  
Use of HAART    
Did not use HAART 60 15.38  
Did use HAART 330 84.62  
Duration of current HAART treatment    
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Eighty-four per cent (328/390) of participants were in stage 1 of WHO-HIV classification, 
and fifteen  per cent (59/390) had a CD4 cell count level below 200 cells/µL.The median 
CD4 count level for the study was 381 cells//µL.  Fifty-one per cent (198/390) of the 
participants had a viral load below 50 copies/ml. Eighty-five per cent (330/390) of 
participants were using HAART. Seventy-three per cent (283/390) of the participants were on 
the HAART treatment for more than one year at the time of Pap smear testing. Seventy-two 
per cent (281/390) of participants had not changed their HAART treatment since the 
treatment was initiated. Eighty-four per cent (41/49) of participants who changed their 
HAART treatment were on the previous HAART treatment for more than one year. Fifty-six 
per cent (219/390) of the participants reported HAART adherence for two sequential visits 
within a year of treatment. 
Table 4.3.2 Current Pap smear results of the participants 
 
 
 
 
Did not use HAART as treatment 60 15.38  
Less than 6 months 17 4.36  
6 months-1 year 30 7.69  
Greater than 1 year 283 72.56  
History of most recent switch of HAART treatment    
Did not use HAART treatment 60 15.38  
Did not switch off HAART treatment 281 72.05  
Did switch off HAART treatment 49 12.56  
If any switch off HAART treament, the duration of the 
previous HAART treatment 
N=49   
Less than 6 months 4 8.16  
6 months-1 year 4 8.16  
Greater than 1year 41 83.67  
Self reporting of adherence to HAART for 2 sequential visits 
within 12 months of treatment 
N=390   
Adherent 219 56.15  
Not adherent 105 26.92  
Participants not on HAART and participants on HAART for a 
period of less than 6 months. 
66 16.92  
Pap smear results Number of participants 
N=390 
Percentages 
% 
Normal 168 43.08 
Abnormal 222 56.92 
 ASCUS 16 4.10 
 AGUS 0 00.00 
 LSIL 142 36.41 
 HSIL 64 16.41 
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Fifty-seven per cent (222/390) of the participants had abnormal Pap smears, of which thirty-
six per cent (142/390) had low squamous intraepithelial lesions and sixteen per cent (64/390) 
had high squamous intraepithelial lesions. 
4.5 Association between WHO staging, and use of and adherence to HAART with    
abnormal Pap smears 
 
Table 4.4.1  WHO staging with abnormal Pap smears 
Variables Normal Pap smears 
N=168 
Abnormal Pap smears 
N=222 
P 
value 
95% confidence 
interval 
WHO 
staging 
Total 
number 
N=390 
Number Percentages Number Percentages   
Stage 1 328 145 44.20 183 55.80   
Stage 2 36 18 50.00 18 50.00 0.508 0.40 -1.58 
Stage 3 26 5 19.20 21 80.80 0.018 1.23-9.04 
Stage 4 0 0 0.00 0 0.00   
  
 
 
 
Figure 1 WHO staging with abnormal Pap smears 
Pearson Chi2(2) = 7.50  p-value= 0.023 
This result indicates that there was a statistical significant relationship between WHO staging 
at the time of Pap smear and abnormal Pap smears (Chi square with two degrees of freedom= 
7.50, p=0.023). WHO stage 3 participants were three time more likely to have abnormal Pap 
44%
50%
19%
56%
81%
Stage 1 Stage 2 Stage 3
Normal pap Smear Abnormal Pap smear
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smears as compared to those with WHO stage 1 (OD 3.3, STD. error 1.7, p=0.018, 95% CI 
1.23-9.04). 
Table 4.4.2 Use of HAART with abnormal Pap smears 
Variables Normal Pap smears 
N=168 
Abnormal Pap smears 
N=222 
Median CD4 
cell count 
level( in 
cell/µL) 
P 
value 
95% 
confidence 
interval 
Use of  
HAART 
Total 
number 
N=390 
Number Percentages Number Percentages    
Did not use 
HAART 
60 18 30.00 42 70.00 227.5   
Did use 
HAART 
330 150 45.40 180 54.60 426 0.028 0.28-0.93 
 
 
Figure 2 Use of HAART with abnormal Pap smears 
Pearson Chi2(1) = 4.9452  p-value= 0.024           
This result indicates that there was a statistical significant relationship between the use of 
HAART and abnormal Pap smears (Chi square with one degree of freedom= 4.9452, 
p=0.024). Abnormal Pap smears results were seen more in participants who did not use 
HAART as compared to those who used HAART [ 42/60, (70.00%) vs.180/330, (54.60%) p-
30%
45%
70%
55%
0%
20%
40%
60%
80%
Did not use HAART Did use HAART
Normal Pap smear Abnormal Pap smear
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0.028, 95% CI: 0.28-0.93], and the median CD4 cell count level was (227.50 cell/µL) is 
lower than the median CD4 cell count of the participants who did use HAART (426 cell/ µL).  
 
Figure 3 Adherence to HAART with abnormal Pap smears 
 Pearson Chi2( 1) =0.0212  p-value=0.884 
This result indicates that there was no relationship between adherents to HAART and 
abnormal Pap smears.  
 
 
Figure 4  Viral load with abnormal Pap smears 
Pearson Chi2( 2) =2.8128  p-value=0.245 
This result indicates that there was no relationship between viral load and abnormal Pap 
smears.  
 
 
 
47% 46%
54% 54%
Adherence to Haart Did not adherence to Haart
Normal Pap Smear Abnormal Pap smear
48%
50%
34%
52%
66%
<400 400-999 > 1000
Normal Pap Smear Abnormal Pap smear
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Table 4.4.3 CD4 cell count with abnormal Pap smears 
Variables Normal Pap smears 
N=168 
Abnormal Pap smears 
N=222 
P-
value 
95% confidence 
interval 
CD4 cell count (in 
cell/µL) 
Total 
number 
N=390 
Number Percentages Number Percentages   
Less than 200 59 12 20.33 47 79.67   
200-349 113 38 33.63 75 66.37 0.071 0.24-1.06 
350-499 101 49 48.51 52 51.49 0.001 0.13-0.57 
Greater than 500 117 69 58.97 48 41.03 0.000 0.09-0.37 
 
 
Figure 5 CD4 cell count with abnormal Pap smears 
Pearson Chi2( 3) =29.8311  p-value=0.001 
This result indicates that there was a statistical significant relationship between the CD4 cell 
count and abnormal Pap smears (Chi square with three degrees of freedom= 29.8311, 
p=0.001) with CD4 cell count levels greater than 500 cells/µL presenting less abnormal Pap 
smears (41.00 %, 48/117) as compared to those with the CD4 cell count less than 350 cells/ 
µL (70.93%, 122/172). 
 
 
20.33
33.63
48.51
58.97
79.67
66.37
51.49
41.03
Less than 200 200-349 350-499 Greater than 500
Normal Pap smears Abnormal Pap smear
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CHAPTER 5 
5.0 DISCUSSION 
This study was conducted to assess the association of WHO staging and adherence to 
HAART among HIV-infected with abnormal cervical smears, attending Dr Yusuf Dadoo 
Hospital. The researcher was satisfied with a 78.00 % response rate.This suggests that the 
study findings are reliable and valid. 
5.1 COMPARISON OF THE RESULTS WITH OTHER STUDIES 
5.1.1  Basic characteristics  
5.1.1.1 Sociodemographic characteristics  
 
A total of 390 HIV-infected women were screened for abnormal cervical smears. They were 
aged between 21 and 65 years with a mean age of 38 ± 8.67 years. The majority of the study 
participants (97.69%, 381/390) were Africans reflecting the demographic composition of the 
population from which the sample was drawn. This ethnic trend was not seen in Cape Town, 
where the majority of the study participants (75.50%, 367/486) were of coloured origin.6 The 
majority of the study participants (47.18%, 184/390) were not married and were singles. This 
observation was also made by Gayman et al14 in Kwazulu Natal. The majority of the study 
participants (74.62 %, 291/390) had pre-matric qualification, contrasts with the findings of 
Swende et al in Nigeria,47 where the majority of their study participants (27.30%, 69/253) had 
no educational background. 
5.1.1.2 Reproductive health and sexual activities of the participants 
 
Most of the study participants (75.90%, 296/390) had their first sexual encounter between 15 
and 19 years of age. This observation concurs with the findings made by Firnhaber et al.35 In 
some studies done in America and Africa,4,17,35,48,59 three per cent of their samples had their 
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first sexual encounter before age 15 years, and revealed a decrease in the rate of the first 
sexual intercourse before 15 years of age. Seventy-seven per cent of participants (302/390) in 
this study had their first pregnancy before 25 years of age. This suggests that a study should 
be done to link early sexual engagement with the age of first pregnancy.  
Ninety-six per cent (374/390) of the participants reported to have had at least one lifetime 
pregnancy and ninety-three per cent (366/390) had at least one child. These observations 
were also found in some studies cited in the literature review,4,50 and the lowest percentage 
(36.00%, 110/280) was found by Tansupswatdikul.29  
This implies the vulnerability of the study participants to develop abnormal cervical smears 
regardless of their HIV status. 
Ninety two per cent (359/390) of the participants reported to have multiple sexual partners. 
The same observation was seen in studies conducted in Johannesburg 35 and in Isreal 51. This 
seems to be higher as reported by Tansupswatdikul et al.(69.00%, 192/280) in the literature.29 
Vaginal discharge seemed to be the most common presentation in those who reported to have 
had a sexually transmitted disease. Genital warts and herpes were found to be at three per 
cent in this population, as compared to another study by Ellerbrock et al.48 with 14.00% 
(46/328) of their study population presenting with genital warts and herpes.  
Seventy-seven per cent (302/390) of the study participants used contraception. Male condoms 
were the most commonly used contraceptive method (60.26%, 182/302). Male condom usage 
was reported to be at 75.00% (756/1010) by Firnhaber et al.28 and at 40.00% (48/120) by 
Moodley et al.41 The study findings were similar to the above-mentioned studies. This 
contrasts with the finding made by Gaym et al.14 reporting Depo-Provera as being the most 
used contraceptive in their study sample, and male condom use in some of the literature, 
which was reported to be 25.00%14 and 16.00%.4, 51 The remaining twenty-three per cent of 
the participants in this study who did not use condoms are a risk for the society, as they will 
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spread HIV-infection. Thus the study participants could get a secondary HIV infection and 
other sexually transmitted infections. 
5.2 Clinical characteristics of the participants 
 
Eighty-four per cent (328/390) of the participants in this study were in stage one WHO-HIV 
classification. In a retropective study of cervical smears in HIV-infected postnatal women at 
Johannesburg Hospital, WHO-HIV stage one was seen in 31.00% (76/248) of the study 
population.52 Though the study sample was almost equal to this study, the difference might 
be due to the selection of the participants (post natal HIV-positive women).  
The study findings of seven per cent (WHO-HIV stage 3) contradict the findings of Memiah 
et al. who found that more than one third of their study participants were in stage three, 
followed by stage four WHO-HIV.50 The difference might be due to the fact that sick patients 
were excluded from this study.  
Fourty four per cents (172/390) of the study participants had a CD4 cell count of less than 
350 cells/µL and thirty per cents (117/390) had a CD4 cell count of greater than or equal to 
500 cells/µL with a median CD4 cell count of 381 cells/µL. This observation contradicts 
other studies that have a median CD4 cell count of 174 cells/µL as seen in Nigeria47 (2012) 
where 41.10%  of those participants (104/253) were on HAART treatment; 267 cells/µL as 
seen in South Africa52 (2011) where 34.00% of those participants (26/76) were on HAART 
treatment; 458 cells/µL as seen in Kenya50 (2012) where 84.30% of the participants 
(578/715) were on HAART treatment. The above finding in this study might explain the 
reason why WHO-HIV stage four participants were not seen. In this study, participants who 
had a CD4 cell count of less than 350 cells/µL had greater risk of developing abnormal Pap 
smears. This suggests that the lower the CD4 cell count the higher the chance of developing 
cervical cancer precursors. 
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The majority (82.40%, 267/324) of the participants who were on HAART had a viral load of 
less than 400 copies/ml and thirteen per cent (41/324)  had a viral load of greater than and 
equal to 1000 copies/ml. As soon as the researcher got this result, advice was given to the 
health workers to get all patients with a viral load greater than 1000 copies/ml to get adherent 
counselling. In a study done by Swende et al in Nigeria47, where the sample size was 253, 
eighty one per cents (205/253) of the study participants had a viral load of greater then than 
400 copies/ml and nineteen per cent ( 48/253) a viral load of less than 400 copies/ml.    
In this study eighty-five per cent (330/390) of the participants used HAART, which implies a 
broader antiretroviral therapy coverage.  
Fifty-six per cent (219/390) of the participants reported that they were adhering to HAART 
for the two sequential visits within 12 months of their treatment. Similar observations were 
seen in a study by Minkoff et al.46 These findings contradicted the study by Leibenson et al. 
in Israel where the adherence rate to HAART was reported to be 86.00%.51  This difference 
might be due to the small study sample in Israel (N=90). The remaining forty-four percent of 
the participants in the present study reported not adherent to HAART. This might lead to the 
occurrence of drug resistance and/or opportunistic infections including cervical cancer. 
5.3 Prevalence of abnormal Pap smears and Pap smear results  
 
The abnormal Pap smear results of the participants was fifty-seven per cent. Similar 
observations were reported in Africa.2,17,35,47 Contrary to the researcher’s observation, the 
prevalence of abnormal Pap smears was found to be below 50.00% in some studies.14,29,49. 
The difference might be due to the study sample and to the degree of illness presented by the 
participants (WHO-HIV stage).  
Among those with abnormal Pap smear results, low-grade squamous intraepithelial lesions 
[36.00%, (142/390)] were the commonest pathology, followed by high-grade squamous cell 
lesions [16.00%, (64/390)]. Similar findings were seen in Dames et al. in United Stated of 
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America49 (2008), where 81.00% of their participants (81/100) were on HAART of which 
31.00% (31/100) had low-grade squamous cell lesions, and 6.00% (6/100) had high-grade 
squamous cell lesions. The above findings contradict with the findings reported by 
Tansupswatdikul et al.29 in Thailand (2009), where 82.10% (230/280) of their participants 
were on HAART, of which 6.40% had LGSIL (18/280) and 12.10% had HGSIL (34/280); 
and by Gaym et al (2007) in South Africa14 with the limitation of no information given about 
how many participants were on HAART, who found  21.00% (24/114) of LGSIL and 4.30% 
(5/114) of HGSIL. The study sample size and prevalence of abnormal Pap smears might have 
played a role in this difference. The present study confirms that there is a high risk of cervical 
precursors in HIV infected women. Hence the emphasis on the importance of the cervical 
smear screening in all HIV-infected women. 
5.4 Association of  WHO staging, Adherence to HAART with abnormal Pap smears 
5.4.1 Association of  WHO staging with abnormal Pap smears 
 
Though there was a statistical significant relationship between WHO staging and abnormal 
Pap smears (Chi square with two degrees of freedom = 7.50, p=0.023), WHO stage 3 
participants seemed to be three times more likely to have abnormal Pap smears than those 
with WHO stage 1 (OD 3.3, STD. error 1.7, p=0.018, 95% CI 1.23-9.04). Thus, the more 
advanced the WHO-HIV stage in a woman, the greater the chance of having an abnormal Pap 
smear.  
This contradicts the findings made by Wise52 in Johannesburg who found that the WHO stage 
did not appear to have an impact on the final analysis of the Pap smear. The difference might 
lie in the fact that the raw data for the WHO classification was largely incomplete, with 
45.00% missing data in Wise’s study as it was a retrospective record review. 
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5.4.2 Association of the use HAART with abnormal Pap smears 
 
There was a statistical significant relationship between the use of HAART and abnormal Pap 
smears (Chi square with one degree of freedom=4.9452, p=0.024). Abnormal Pap smears 
were seen more in participants who did not use HAART as compared to those who used 
HAART [42/60, 70.00% vs. 180/330, 55.00%, p=0.028, 95% CI 0.28-0.93], with a median 
CD4 count of 426 cells/µL. This concurs with the observations  made by many authors in the 
literature.17,41,50,51 Thus, the immune reconstitution resulting from HAART use might not be 
sufficient to prevent the development of abnormal cervical smears in HIV-infected women. 
This observation might be due to the fact that women started HAART often with below 200 
cells/µL and so would have had lower CD4 cell count nadirs and developed cervical 
dysplasias, and with immune-reconstitution did not have any improvement of the disease. 
The period on HAART was not looked at and it may be a confounder in this finding.It has a 
valid merit to be looked at, as another research topic.  
5.4.3 Association of adherence to HAART with abnormal Pap smears 
 
There was no association between adherence  to HAART and abnormal Pap smears in HIV-
infected women who participated in this study (p=0.884). The same observation was made by 
Leibenson et al51 in Israel where HAART compliance was not found to have an impact on 
HPV prevalence. (p=0.525). The above observation contradicts the findings by Minkoff et 
al46 in a propective cohort study in the United State of America where adherent to  HAART 
was associated with a significant reduction of squamous intraepithelial lesions. This 
difference may be attributed to the facts that it was a prospective cohort study, to HAART 
regimens offered to their study participants and the period on HAART. The patient’s self-
report of HAART may have also contributed to this difference as an information biais can 
impact largely into the final result of this current study.  
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5.4.4 Association of viral load with abnormal Pap smears  
 
Even though the viral load is a good surrogate for antiretroviral drug adherence no 
relationship between viral load and abnormal Pap smears was found (p=0.245).This finding 
concurs with the cross-sectional study done by Leibenson et al51 in Israel in which no 
statistical significant effect of viral load on HPV prevalence was found ( p=0.277). In a cross-
sectional study by Cardillo et al54 in United States of America, the viral load from the patients 
with SILs was significantly higher than that from those with normal Pap smears (109,316 
copies/mL vs. 41,602 copies/ml; p=0.006). The difference with this current study may be 
related to the duration of the study (5 years), HAART regimen and the absence of treatment 
compliance data. The same observation was made by Swende et al 47 in Nigeria where the 
viral load of their study participants on HAART was significantly higher in women with SIL 
as compared with that of women without SIL (102,705 vs. 64,391copies/ml, recpectively; 
p=0.002). The difference may be due to the fact that in their study more participants (81.00%, 
205/253) had a viral load of greater than 400 copies/ml as compared to those of the current 
study (17.60%, 55/324). 
Though there was no significant relationship between viral load and abnormal Pap smears, 
the graph (see fig.4 on page 25) showed that the higher the viral load count, the more 
abnormalities were seen in the Pap smears.This finding was similar to the graph on the 
association between WHO staging and abnormal Pap smears see fig.1 on page 23.Since this 
observation was not part of the study objectives, the researcher suggests another study 
looking at this link. 
  5.4.5 Association of CD4 count levels with abnormal Pap smears  
 
There was a significant statistical relationship between CD4 cell count levels and abnormal 
Pap smears (Chi square with three degrees of freedom=29.8311, p=0.001). The participants 
with the CD4 cell count levels greater than 500 cells/µL presenting less abnormal Pap smears 
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as compared to those with CD4 cell count of less than 350 cells/µL. If HAART treatment is 
being initiated at CD4 cell count level greater than 500 cells/µL, this might help reduce the 
prevalence of cervical dysplasias. This association with the immune status of HIV-infected 
women has been reported by many authors4,52,55 in the literature, with particularity on more 
Pap smear abnormalities with a CD4 cell count level <200 cells/µL.13,28,29,47,50,53  A CD4 cell 
count of less than 350 cells/µL could be a useful tool in the stratification of the risk in 
developing cervical abnormalities or cervical cancer in HIV-positive women. 
Looking at the above findings in 5.1.6, 5.1.7 and 5.1.10, the researcher concludes that: 
1. The more immunosuppressed a woman is, the higher her chance of developing 
cervical cancer precursors. The WHO staging is important in stratifying the risk of 
developing abnormal Pap smear in HIV-infected women. 
2.  HAART treatment and the CD4 count greater than 500 cells/µL were offering a 
protective role in the development of abnormal cervical lesions.  
3. Adherence to HAART and viral load did not have any protective role in the 
development of abnormal Pap smears in HIV-positive women attending Dr Yusuf 
Dadoo hospital. 
4. The high risk group to have abnormal Pap smear in this study was found to be the 
participants with the CD4 cell count of ≤ 350 cells/µL and the viral load ≥1000 
copies/mm3. The self-reported adherence level did not show any impact.   
5.5 Limitations 
 
 As the study is a cross-sectional study, it looked only at the associations and did not 
look at the effectiveness of HAART on abnormal Pap smears. 
 This study did not explore the CD4 cell count nadirs, the WHO staging at the start of 
HAART and the period on HAART. Such data might have an impact on the 
35 
 
establishment of an association between the CD4 cell count, and the use of HAART 
with abnormal Pap smears. 
 This study did not explore the in depth the sexual history of the participants. Such 
data might have  an influence on the demographic and reproductive characteristics of 
the participants. 
 The link between the viral load levels and the WHO staging of the study participants 
were not explored, such a data might have had an influence on the Pap smears results. 
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CHAPTER 6 
6.0 CONCLUSION AND RECOMMENDATIONS 
Abnormalities on Pap smears in HIV-infected patients have been reported in the literature 
and many predicting factors for these abnormalities have been cited. Among these factors 
HIV-positive status was one of the independent factors found to be related to abnormal Pap 
smears. Others factors like WHO staging, and use of HAART and CD4 cell count levels are 
important factors to be considered when looking at abnormal Pap smears in HIV-infected 
women. These factors may be used to stratify the cervical smear risk in many under-
resourced and under-developed countries, so that preventative measures can be taken and 
implemented. 
In our research, an association was found between WHO staging, the use of HAART and  
current CD4 cell count levels and abnormal Pap smears among HIV-infected women 
attending Dr Yusuf Dadoo Hospital. 
Therefore, some recommendations follow: 
 Cervical cancer screening is imperative in HIV-infected women and guidelines 
considering the severity of immunosuppression should be provided for the health care 
workers.Targets should be set and monitored at the health care clinics. 
 If HAART is being initiated at CD4 cell count level greater than 500 cells/µL, this 
might help reduce the prevalence of cervical dysplasias. 
 Adherence counselling should be given generally to all HIV-infected women and 
specifically to those at high risk for defaulting. 
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Annexure 1  Questionnaire  
WHO staging, adherence to HAART and abnormal cervical smears among 
HIV-infected women attending Dr Yusuf Dadoo Hospital. 
 
Please answer the following questions. 
     
1. Code number .……………………      
2. How old are you?.............................. 
3. What ethnic group do you belong to?       African                      White                                                     Coloured 
               Indian        Coloured                                            Others   
4. Are you married? No                         Yes               
5. If you are not, what is your status?  
Cohabiting  Divorced                  widowed                      Single             
6.  Are you working? No                   Yes     
7. If you are not working, what are you doing?     
Student                      Pensioner                          unemployed                
8. What is your educational level? 
None                      Pre-matric                    Matric                   Post-matric 
     9.  At what age did you have your first sexual encounter?……..  
     10.  How old were you when you first fell pregant?……. 
    11.  How many times did you fall pregnant?......... 
    12. How many children have been born to you after completing 7 months of 
           pregnancy?........... 
   
    13. Have you been treated for Sexually transmitted disease by a doctor/Nurse?                                         
 No                         Yes     
   14. If yes, what type of  Sexually transmitted disease  was it?                        
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        Genital ulcer             Genital warts                                  Herpes simplex                
                                    Vaginal discharge                                              Not sure  
   15. How many sexual partner/s do you have in a life time ?………  
   16.  Do you use contraception (prevention)?             No                             Yes 
   17. If yes, what type of prevention do you use? condom                  Injection             
  
                                                  Oral contraceptive pills                          Others 
 
   
 
Thank you for your participation. 
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Annexure 2. Data capture sheet 
 
Code number    
WHO staging 1   
2   
3   
4   
CD4 COUNT <200   
200-349   
350-499   
>500   
VIRAL LOAD <50   
50-399   
400-999   
>1000   
HAART OR NOT No   
Yes   
Duration on  current 
HAART 
<6 months   
6 months -1 year   
>1 year   
Most recent switch off 
HAART 
No   
Yes   
If any switch off 
HAART,duration on 
previous HAART 
<6 months   
6 months -1 year   
>1 year   
Self reporting of 
adherence for 2 sequential 
visits with in 12 months 
No   
Yes   
Current Pap smear result Normal   
 ASCUS   
 AGUS   
 LSIL   
 HSIL   
 UNKNOWN   
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Annexure 3  Participant’s information sheet and consent form 
HREC protocol approval number: M130111 
 
Study title: WHO staging, adherence to HAART with abnormal cervical smear among HIV-
infected women Dr Yusuf Dadoo Hospital. 
Study doctor: Dr A.C Katumba, a Registrar in Family Medicine at the University of the 
Witwatersrand.  
Purpose of the research: The study doctor is conducting this study as a requirement towards 
the completion of the MMed (Family Medicine) degree. 
Institution: University of the Witwatersrand. 
Introduction: 
 
Good day, my name is Dr Appolinaire Ciamalenga Katumba, I am a Fouth-year registrar in 
the Department of Family Medicine at the University of the Witwatersrand. I would like to 
invite you to participate in a study entitled “WHO staging, adherence to HAART with 
abnormal cervical smear among HIV-infected women Dr Yusuf Dadoo Hospital”. I am doing 
this study as part of the requirements for specialization in Family Medicine.  
Before agreeing to participate in this study, it is important that you read and understand the 
following explanation of the purpose of the study, the study procedures, benefits, risks, 
discomfort, and precautions as well as your right to withdraw from the study at any time. 
This information leaflet is to help you to decide if you would like to participate. You should 
fully understand what is involved before you agree to take part in this study.  
Purpose of the study: 
 
The study is assessing the association between the WHO staging (different degrees of the 
HIV disease) and adherence to HAART (ability to take the HIV treatment regularly without 
skipping a day) and abnormal cervical smears. Many countries do not have CD4 count tests 
and rely on WHO clinical staging in order to assess the immunological status of the patients. 
This study may help those countries with limited resources to stratify the risk of developing 
cervical cancer in HIV-positive women. 
 
Procedure: 
 
As part of your treatment at this clinic you will be examined and you will be offered a Pap 
smear. The Pap smear is a test done to find abnormal cells on the mouth of the womb which 
may become a cancer if left untreated. If your Pap smear test is abnormal you will be referred 
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for further tests. The Pap smear result will be ready in four weeks time. The Pap smear may 
be uncomfortable. 
I woul also like to ask you some questions about yourself this will take about 15 minutes. 
Some of the questions may cause you some embarrassment and you do not then have to 
answer. I would also like to look at your medical records to see and record some factors 
related to your management. I would like to record the data like CD4 count levels, viral load, 
HAART or not, period on HAART, whether your are taking your treatment regularly or not. 
Risks and benefits: 
 
There are not foreseeable risks associated with your participation in the study. You will not 
receive any payment for participating in the study. Your treatment at this clinic will be the 
same whether you are in the study or not. 
Confidentiality and Data storage: 
 
All the information that you provide will be kept confidential. I will not be required to record 
your name or date of birth on the questionnaire or data capture sheet and you will not be 
directly identified in the research report. The questionnaire and the data capture sheet will be 
coded. Your name and/or your date of birth will not appear on any data collection tool used 
in the study. 
Are there any restrictions concerning my participation in this study? 
 If you are pregnant during the study period, you may not take part in the study. 
 If you are on your period (menstruation), the Pap smear test will be done only when 
your period is over.  
Rights as a participant in this study: 
 Your participation in this study is entirely voluntary and you can decline to 
participate, or stop at any time, without stating any reason. 
Withdrawal: 
 Your withdrawal will not affect your access to other medical care. 
Research results: 
 
If you have any questions regarding this research you can ask me now or phone me on this 
number 0823069325 or e-mail me. 
A research report will be submitted to the University of the Witwatersrand. You may request 
a copy of the report or any other feedback and information that you may require. Kindly 
contact me on e-mail: ackatumba@gmail.com or 0823069325 
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Complaints: 
 
The HUMAN RESEARCH ETHICS COMMITTEE (MEDICAL) of the University of the 
Witwatersrand has approved this study. Clearance certificate No: M130111 
If you have concerns or complaints about the conduct of this study please contact the Wits 
Research Office at 011 717 1234 
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     INFORMED CONSENT 
                                 UNIVERSITY OF THE WITWATERSRAND 
 
 I hereby confirm that I have been informed by the study doctor, Dr A.C Katumba, 
about the nature, conduct, benefits and risks of the study: WHO staging, adherence to 
HAART and abnormal cervical smears among HIV-infected women attending Dr 
Yusuf Dadoo hospital. Clearance certificate No: M130111 
 I have  also received, read, and understood the above information (Participant 
Information Leaflet and Informed Consent) regarding the study. 
 I am aware that the results of the study, including personal details regarding my sex, 
age, date of birth, initials and diagnosis will be anonymously processed into a study 
report. 
 In view of the requirements of research, I agree that the data collected during this 
study can be processed in a computarised system by the study doctor. 
 I may, at any stage, without prejudice, withdraw my consent and participation in the 
study. 
 I have had sufficient opportunity to ask questions and (of my own free will) declare 
myself prepared to participate in the study. 
Participant:        Name:………………………………… 
                             Signature/ Thumbprint: 
                             Date and Time:……………………..... 
I, Dr A.C Katumba, herewith confirm that the above participant has been fully informed 
about the nature, conduct and risks of the above study. 
Study doctor:     Name:………………………………… 
                             Signature/ Thumbprint: 
                             Date and Time:…………………….. 
Translator/ Other person explaining informed consent form……….(Designation): 
                            Name……………………….Signature…………. Date/ Time……… 
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Annexure 4.       HREC’s Clearance Certificate 
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Annexure 5.         Permission letter letter from the West Rand Health 
District’s  Director 
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Annexure 6.           Permission letter from the Chief Executive Officer of Dr 
Yusuf Dadoo hospital. 
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Annexure 7.   Flow chart of the research. 
 
 
 
 
 
 
 
 
 
 
 
          VS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
      HIV-positive women who are willing to do a Pap smear at the time of   
consultation 
Normal Pap smears results
   
Abnormal Pap smears results 
 
 WHO staging 
 Current CD4 count levels 
 Not on HAART 
 On HAART 
 Current Viral load 
 Not adherent 
 Adherent 
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Annexure 8. WHO staging 
WHO HIV CLINICAL STAGING (2006) 
STAGE 1: 
 ASYMPTOMATIC 
 PERSISTENT GENERALIZED LYMPHADENOPATHY 
STAGE 2: 
 UNEXPLAINED MODERATE WEIGHT LOSS (<10% OF PRESUMED OR MEASURED 
BODY WEIGHT) 
 RECURRENT RESPIRATORY TRACT INFECTIONS (SINUSITIS, TONSILLITIS, OTITIS 
MEDIA AND PHARYNGITIS) 
 HERPES ZOSTER 
 ANGULAR CHELITIS 
 RECURRENT ORAL ULCERATION 
 PAPULAR PRURITIC ERUPTION 
 SEBORRHOEIC DERMATITIS 
 FUNGAL NAIL INFECTIONS 
STAGE 3: 
 UNEXPLAINED SEVERE WEIGHT LOSS (>10% OF PRESUMED OR MEASURED 
BODY WEIGHT) 
 UNEXPLAINED CHRONIC DIARRHOEA FOR LONGER THAN ONE MONTH 
 UNEXPLAINED PERSISTENT FEVER (ABOVE 37.5 0 C INTERMITTENT OR 
CONSTANT, FOR LONGER THAN ONE MONTH. 
 PERSISTENT ORAL CANDIDIASIS 
 ORAL HAIRY LEUKOPLAKIA 
 PULMONARY TUBERCULOSIS 
 SEVERE BACTERIAL INFECTIONS (SUCH AS PNEUMONIA, EMPYEMA, 
PYOMYOSITIS, BONE OR JOINT INFECTION, MENINGITIS OR BACTERAEMIA) 
 ACUTE NECROTISING ULCERATIVE STOMATITIS, GINGIVITIS OR PERIODONTITIS 
 UNEXPLAINED ANAEMIA (<8G/dl), NEUTROPAENIA (<0.5 X 109 PER LITRE) 
AND/OR CHRONIC THROMBOCYTOPAENIA (<50 X 109 PER LITRE) 
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STAGE 4: 
 HIV- WASTING SYNDROME (WEIGHT LOSS OF > 10%, PLUS EITHER 
UNEXPLAINED CHRONIC DIARRHOEA (> 1MONTH) OR CHRONIC WEAKNESS AND 
UNEXPLAINED PROLONGED FEVER (> 1 MONTH). 
 PNEUMOCYSTIS PNEUMONIA 
 RECURRENT SEVERE BACTERIAL PNEUMONIA 
 CHRONIC HERPES SIMPLEX INFECTION (OROLABIAL, GENITAL OR ANORECTAL 
OF MORE THAN ONE MONTH’S DURATION OR VISCERAL AT ANY SITE) 
 OESOPHAGEAL CANDIDIASIS (OR CANDIDIASIS OF TRACHEA, BRONCHI OR 
LUNGS) 
 EXTRAPULMONARY TUBERCULOSIS 
 KAPOSI’S SARCOMA 
 CMV INFECTION (RETINITIS OR INFECTION OF OTHER ORGANS) 
 CNS TOXOPLASMOSIS 
 HIV ENCEPHALOPATHY (DISABILITY COGNITIVE AND/ OR MOTOR 
DYSFUNCTION INTERFERING WITH ACTIVITIES OF DAILY LIVING, 
PROGRESSING OVER WEEKS TO MONTHS, IN THE ABSENCE OF A CONCURRENT 
ILLNESS OR CONDITION OTHER THAN HIV INFECTION WHICH COULD EXPLAIN 
THE FINDINGS) 
 EXTRAPULMONARY CRYPTOCOCCOSIS INCLUDING MENINGITIS 
 DISSEMINATED NON-TUBERCULOUS MYCOBACTERIAL INFECTION 
 PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY 
 CHRONIC CRYPTOSPORIDIOSIS 
 CHRONIC ISOSPORIASIS 
 DISSEMINATED MYCOSIS (EXTRA-PULMONARY HISTOPLASMOSIS OR 
COCCIDIOMYCOSIS 
 RECURRENT SEPTICAEMIA (INCLUDING NON-TYPHOIDAL SALMONELLA) 
 LYMPHOMA (CEREBRAL OR B-CELL NON-HODGKIN’S) 
 INVASIVE CERVICAL CARCINOMA 
 ATYPICAL DISSEMINATED LEISHMANIASIS 
 SYMPTOMATIC HIV-ASSOCIATED NEPHROPATHY 
 SYMPTOMATIC HIV-ASSOCIATED CARDIOMYOPATHY 
